Skip to main content
. 2015 Jun 15;33(21):2353–2360. doi: 10.1200/JCO.2015.60.9271

Fig 5.

Fig 5.

(A, B) Disease-free survival (DFS) and (C, D) overall survival (OS) in 2,879 patients with hormone receptor–positive, human epidermal growth factor receptor 2–nonoverexpressing breast cancer, based on (A, C) Kaplan-Meier estimates by treatment arm and (B, D) estimated hazard ratios (HRs) and 95% CIs from univariable Cox models in experimental arms (weekly paclitaxel [P1], docetaxel every 3 weeks [D3], and weekly docetaxel [D1]) compared with standard arm (paclitaxel every 3 weeks [P3]).